Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Sep;20(9):1013-1014.
doi: 10.1016/S1473-3099(20)30270-X. Epub 2020 Apr 3.

Baricitinib for COVID-19: a suitable treatment? - Authors' reply

Peter J Richardson  1 , Mario Corbellino  2 , Justin Stebbing  3
Affiliations
Comment

Baricitinib for COVID-19: a suitable treatment? - Authors' reply

Peter J Richardson et al. Lancet Infect Dis. 2020 Sep.
No abstract available

PubMed Disclaimer

Comment on

  • COVID-19: combining antiviral and anti-inflammatory treatments.
    Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P. Stebbing J, et al. Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27. Lancet Infect Dis. 2020. PMID: 32113509 Free PMC article. No abstract available.
  • Baricitinib for COVID-19: a suitable treatment?
    Favalli EG, Biggioggero M, Maioli G, Caporali R. Favalli EG, et al. Lancet Infect Dis. 2020 Sep;20(9):1012-1013. doi: 10.1016/S1473-3099(20)30262-0. Epub 2020 Apr 3. Lancet Infect Dis. 2020. PMID: 32251638 Free PMC article. No abstract available.

References

    1. Richardson P, Griffin I, Tucker C. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30–e31. - PMC - PubMed
    1. Stebbing J, Phelan A, Griffin I. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20:400–402. - PMC - PubMed
    1. Cameron MJ, Ran L, Xu L. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol. 2007;81:8692–8706. - PMC - PubMed
    1. Channappanavar R, Fehr AR, Zheng J. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019;130:3625–3639. - PMC - PubMed
    1. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. - PMC - PubMed